Tyrosine Kinases as Targets for Cancer Therapy Krause DS, Van Etten RA N Engl J Med 2005;353(2):172-87. Krause DS, Van Etten RA N Engl J Med 2005;353(2):172-87.

Slides:

Advertisements

Similar presentations

CELL COMMUNICATION. YOU MUST KNOW… THE 3 STAGES OF CELL COMMUNICATION: RECEPTION, TRANSDUCTION, AND RESPONSE HOW G-PROTEIN-COUPLED RECEPTORS RECEIVE CELL.

Advertisements

Acute Myelogenous Leukemia and its Impact on the Immune System

Chapter 11 Cell Communication. Cell Signaling Evolved early in the History of Life.

Chapter 11 Cell Communication. Question?  How do cells communicate?  By “ cellular ” phones.  But seriously, cells do need to communicate for many.

Enzyme-linked Cell Surface Receptors 16 April 2007.

PDGF β Receptor. Protein 1106 amino acid protein Weinberg Fig 5.10.

Ligand Receptor Cortisol Receptor is located in the cytosol Retinoid Receptors are in the nucleus Target gene in the nucleus Regulation of Transcription.

Jayanti Tokas1, Rubina Begum1, Shalini Jain2 and Hariom Yadav2

Anticancer Therapy: Kinase Inhibitors Charles Harrell.

Basic Concepts of Metabolism

The 3 Steps.  Intracellular Receptors ◦ Proteins in the cytoplasm or in the nucleus ◦ Example: transcription factors  Receptors in the Plasma Membrane.

Manifestation of Novel Social Challenges of the European Union in the Teaching Material of Medical Biotechnology Master’s Programmes at the University.

Advanced Cancer Topics Journal Review 4/16/2009 AD.

Regulation of the Cell Cycle. Molecular Control System Normal growth, development and maintenance depend on the timing and rate of mitosis Cell-cycle.

Targeted Therapies - little & large explained Chris Clarke Macmillan Lead Pharmacist LNR Cancer Network.

Gene Transcription G0G0 G1G1 Priming S G2G2 M Cell Cell Cycle Growth Factors + Growth Factors & Cell Cycle Receptors.

Chapter 6-10 AP Biology. Define phagocytosis and pinocytosis. What does it mean for a cell to have a concentration gradient?

Here are some CML slides that may be helpful for your presentation.

Computational biology of cancer cell pathways Modelling of cancer cell function and response to therapy.

BIOL 445 – CANCER BIOLOGY PRESENTATION

Cell Communication Chapter 9. Please note that due to differing operating systems, some animations will not appear until the presentation is viewed in.

Cell Signaling basics.

AP Biology Chapter 11 Cell Communication. AP Biology The Cellular “Internet”  Within multicellular organisms, cells must communicate with one another.

Personalized Lung Cancer Treatment: Targeting Stem Cell Pathways David M. Jablons, M.D. Professor and Chief Thoracic Surgery Ada Distinguished Professor.

Cell Communication.

Cell Signaling. Local Signaling Paracrine Paracrine Synaptic Synaptic.

Cell Communication Chapter 9.

The Membrane Plays a Key Role in a Cell’s Response to Environmental Signals Cells can respond to many signals if they have a specific receptor.

Mechanism of action of hormones acting on cell surface By Dr. Umar M.T.

Copyright © The McGraw-Hill Companies, Inc. Permission required for reproduction or display. CytoplasmExternal environment Membrane receptor Intracellular.

Negative regulation of cell cycle by intracellular signals Checkpoint p53 detects DNA damage & activates p21 p21 inhibits cdk2-cyclinA Intracellular Regulation.

Transduction of Extracellular Signals Specific receptors in plasma membranes respond to external chemicals (ligands) that cannot cross the membrane: hormones,

Date of download: 6/3/2016 Copyright © American College of Chest Physicians. All rights reserved. Tissue Factor, Thrombin, and Cancer * Chest. 2003;124(3_suppl):58S-68S.

Samsung Genome Institute Samsung Medical Center

An Introduction to Medicinal Chemistry 3/e PROTEINS AS DRUG TARGETS:

Epidermal growth factor receptor tyrosine kinase inhibitors as initial therapy for non- small cell lung cancer: Focus on epidermal growth factor receptor.

Lung Cancer Tumour Markers

Cell Signaling Pathways – A Case Study Approach

Figure 1. Resistance mechanism against first generation epidermal growth factor receptor tyrosine kinase inhibitor (EGFR-TKI). (A) Mutations in the EGFR.

Arne R. M. van der Bilt, Elisabeth G. E

Inducing Angiogenesis

Biologic therapy of inflammatory bowel disease

ד"ר אלה עברון אונקולוגיה ומכון השד אסף הרופא

Chap. 16 Problem 1 Cytokine receptors and RTKs both form functional dimers on binding of ligand. Ligand binding activates cytosolic kinase domains which.

M.B.Ch.B, MSC, DCH (UK), MRCPCH

c-Kit as a Novel Potential Therapeutic Target in Colorectal Cancer

Cell to Cell Communication via Enzyme Linked Receptors

Nat. Rev. Clin. Oncol. doi: /nrclinonc

Extracellular Regulation of Apoptosis

Biologic therapy of inflammatory bowel disease

Figure 1 A schematic representation of the HER2 signalling pathway

دکتر مجیری داروساز متخصص فارماکولوژی

Figure 1 Therapeutic targeting of the B-cell receptor (BCR)

Targeted Therapies in Melanoma: Translational Research at Its Finest

Development of PI3K/AKT/mTOR Pathway Inhibitors and Their Application in Personalized Therapy for Non–Small-Cell Lung Cancer Vassiliki Papadimitrakopoulou,

The chimeric Trk protein, composed by the TK domain with ATPase activity and a TM loop along with a fusion partner. The chimeric Trk protein, composed.

Vascular Endothelial Growth Factor (VEGF) Pathway

Cell Communication CHAPTER 11.

The RAF Inhibitor Paradox Revisited

Vascular Endothelial Growth Factor and Epidermal Growth Factor Signaling Pathways as Therapeutic Targets for Colorectal Cancer Thomas Winder, Heinz–Josef.

M.B.Ch.B, MSC, PhD, DCH (UK), MRCPCH

Yan Feng, MD, Praveena S. Thiagarajan, PhD, Patrick C. Ma, MD

Oncogenic ALK signaling.

Masaru Katoh Journal of Investigative Dermatology

Platelet-derived growth factor (PDGF) signalling pathway.

The new kid on the block(ade) of the IGF-1 receptor

Notch signaling from tumor cells: A new mechanism of angiogenesis

Brief Review – Growth Factors and Receptors

Figure 2 Mechanisms of RET activation in cancer

Presentation transcript:

Tyrosine Kinases as Targets for Cancer Therapy Krause DS, Van Etten RA N Engl J Med 2005;353(2): Krause DS, Van Etten RA N Engl J Med 2005;353(2):

Introduction Protein tyrosine kinases (TKs) catalyze the transfer of a phosphate group from ATP to tyrosine residues in proteins. There are two classes of TKs: –Receptor TKs-transmembrane proteins with extracellular ligand binding domains and intracellular kinase domains. –Nonreceptor TKs-lack transmembrane domains and are found in the cytosol, nucleus or near the plasma membrane Receptor TKs include EGF and VEGF receptors, PDGF receptors, FLT-3 and KIT. Nonreceptor TKs are typified by c-ABL. Krause DS, Van Etten RA. N Engl J Med 2005;353(2):

Krause DS, Van Etten RA. New Engl J Med 2005;353(2): © 2005 Massachusetts Medical Society. All rights reserved. Regulation of TK Activity-Inactive State

Krause DS, Van Etten RA. New Engl J Med 2005;353(2): © 2005 Massachusetts Medical Society. All rights reserved. Regulation of TK Activity-Activated State

TK Dysregulation in Cancer Dysregulation of TK activity may occur in several ways. –Increased expression of receptor TK and/or its ligand –Mutation that alters autoregulation of the TK –Fusion with a partner protein that results in constitutive activation of the TK Aberrant TK activation may result in increased cell survival and proliferation, and in drug resistance. –In tumors, increased angiogenesis and invasiveness may result. TKs can be inhibited pharmacologically through multiple mechanisms. Krause DS, Van Etten RA. N Engl J Med 2005;353(2):

Krause DS, Van Etten RA. New Engl J Med 2005;353(2): © 2005 Massachusetts Medical Society. All rights reserved. Small Molecule Inhibitors of Receptor TKs

Krause DS, Van Etten RA. New Engl J Med 2005;353(2): © 2005 Massachusetts Medical Society. All rights reserved. Therapeutic Targeting of Constitutively Activated Receptor TKs

Krause DS, Van Etten RA. New Engl J Med 2005;353(2): © 2005 Massachusetts Medical Society. All rights reserved. Therapeutic Targeting of Activated Fusion TK Proteins

Krause DS, Van Etten RA. New Engl J Med 2005;353(2): © 2005 Massachusetts Medical Society. All rights reserved. Limitations of TK-Targeted Therapies: Development of Resistance

Reprinted with permission from Rini BJ. Clin Cancer Res 2007;13(4): Figure 1. Mechanism of Action of Inhibitors of the VEGF/VEGFR Signaling Pathway